Research Progress of Flow Cytometry in Diagnosis and Treatment of Myelodysplastic Syndrome--Review.
10.19746/j.cnki.issn.1009-2137.2025.04.044
- Author:
Qiu-Cheng ZHANG
1
;
Bao-An CHEN
1
;
Jian CHENG
1
Author Information
1. Medical School of Southeast University, Department of Hematology of Zhongda Hospital, Nanjing 210009, Jiangsu Province, China.
- Publication Type:English Abstract
- Keywords:
myelodysplastic syndrome;
flow cytometry;
immunophenotype detection;
diagnosis;
prognosis;
efficacy assessment
- MeSH:
Flow Cytometry;
Myelodysplastic Syndromes/therapy*;
Humans;
Leukemia, Myeloid, Acute/diagnosis*;
Immunophenotyping/methods*;
Prognosis
- From:
Journal of Experimental Hematology
2025;33(4):1222-1227
- CountryChina
- Language:Chinese
-
Abstract:
Flow cytometry (FCM), as an important method for the diagnosis of acute myeloid leukemia (AML), has been widely used in myelodysplastic syndrome (MDS) in recent years. FCM can effectively identify and characterize abnormal hematopoietic cells through immunophenotyping, particularly in the diagnosis of MDS with insignificant morphological abnormalities. Additionally, FCM can monitor disease progression and minimal residual disease (MRD) by detecting phenotypic changes and evaluate treatment efficacy. This article reviews the latest research progress of FCM in the immunophenotyping, prognosis and efficacy evaluation of MDS.
